tiprankstipranks
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges
Company Announcements

Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges

Pick the best stocks and maximize your portfolio:

Syros Pharmaceuticals ( (SYRS) ) has shared an announcement.

Syros Pharmaceuticals faces significant challenges as it terminates its collaboration with QIAGEN, following the failure of its SELECT-MDS-1 Phase 3 trial to meet key endpoints. This resulted in a default under its Loan Agreement with Oxford Finance, demanding nearly $43.7 million repayment. In response, Syros has initiated a drastic workforce reduction of 94% to curb costs and maximize stakeholder value, highlighting its ongoing financial struggles.

See more insights into SYRS stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlySyros Pharmaceuticals downgraded to Hold from Buy at TD Cowen
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App